BCDA Share Price Performance
US$1.21
-0.74 (-37.95%)
79.8% undervalued intrinsic discount
US$6.00
Fair Value
Price US$1.21
AnalystLowTarget US$6.00
AnalystConsensusTarget US$15.50
AnalystHighTarget US$25.00
Fair ValueUS$6.00
Share Pricen/a
BioCardia, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
BCDA Community Narratives
AN
Fair Value
·Fair Value US$6 79.8% undervalued intrinsic discount
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$15.5 92.2% undervalued intrinsic discount
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$25 95.2% undervalued intrinsic discount
Cell Therapy Approvals And Heart Failure Trends Will Support Strong Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cell Therapy Approvals And Heart Failure Trends Will Support Strong Long Term Opportunity
Catalysts About BioCardia BioCardia develops cell-based therapies and delivery systems for patients with cardiovascular disease. What are the underlying business or industry changes driving this perspective?Read more
AN
US$25
95.2% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
283.75x
Price in 2029
US$0
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
Catalysts About BioCardia BioCardia develops cell and biotherapeutic delivery therapies aimed at treating cardiovascular disease. What are the underlying business or industry changes driving this perspective?Read more
AN
US$15.5
92.2% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
319x
Price in 2029
US$0
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
Catalysts About BioCardia BioCardia develops cell therapies and delivery systems for cardiovascular diseases, focusing on heart failure and ischemic heart conditions. What are the underlying business or industry changes driving this perspective?Read more
AN
US$6
79.8% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
97.15x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Cell Therapy Approvals And Heart Failure Trends Will Support Strong Long Term Opportunity
Fair Value: US$25 95.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
Fair Value: US$15.5 92.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
Fair Value: US$6 79.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioCardia, Inc. Key Details
About BCDA
- Founded
- n/a
- Employees
- 19
- CEO
- WebsiteView website
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
